These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34398175)

  • 21. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.
    Kjaergard LL; Als-Nielsen B
    BMJ; 2002 Aug; 325(7358):249. PubMed ID: 12153921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Authors and their financial ties.
    Turpin DL
    Am J Orthod Dentofacial Orthop; 2002 Nov; 122(5):449. PubMed ID: 12439469
    [No Abstract]   [Full Text] [Related]  

  • 23. Conflict of Interest and the CREATE-X Trial in the New England Journal of Medicine.
    Ozaki A
    Sci Eng Ethics; 2018 Dec; 24(6):1809-1811. PubMed ID: 28916944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events in randomized trials: neglected, restricted, distorted, and silenced.
    Ioannidis JP
    Arch Intern Med; 2009 Oct; 169(19):1737-9. PubMed ID: 19858427
    [No Abstract]   [Full Text] [Related]  

  • 25. Addressing ethical considerations and authors' conflict of interest disclosure in medical journals in Iran.
    Heidari A; Adeli SH; Mehravaran S; Asghari F
    J Bioeth Inq; 2012 Dec; 9(4):457-62. PubMed ID: 23188405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-declared stock ownership and association with positive trial outcome in randomized controlled trials with binary outcomes published in general medical journals: a cross-sectional study.
    Falk Delgado A; Falk Delgado A
    Trials; 2017 Jul; 18(1):354. PubMed ID: 28747226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Authors of clinical trials seldom reported details when declaring their individual and institutional financial conflicts of interest: a cross-sectional survey.
    Hakoum MB; Noureldine H; Habib JR; Abou-Jaoude EA; Raslan R; Jouni N; Hasbani DJ; Lopes LC; Guyatt G; Akl EA
    J Clin Epidemiol; 2020 Nov; 127():49-58. PubMed ID: 32512186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Are treatment effects or adverse effects of significance for the association between financing and conclusions in randomized trials?].
    Als-Nielsen BE; Chen W; Gluud CN; Gluud LL
    Ugeskr Laeger; 2004 Apr; 166(18):1676-8. PubMed ID: 15174406
    [No Abstract]   [Full Text] [Related]  

  • 29. ALLHAT, or the soft science of the secondary end point.
    Neely DB
    Ann Intern Med; 2004 Jul; 141(1):77. PubMed ID: 15238380
    [No Abstract]   [Full Text] [Related]  

  • 30. Unreported financial disclosures in a study of migraine and cardiovascular disease.
    Kurth T; Gaziano JM; Cook NR; Logroscino G; Diener HC; Buring JE
    JAMA; 2006 Aug; 296(6):653-4; author reply 654. PubMed ID: 16896106
    [No Abstract]   [Full Text] [Related]  

  • 31. Authors' financial interests should be made known to manuscript reviewers.
    de Melo-Martín I; Intemann K
    Nature; 2007 Jul; 448(7150):129. PubMed ID: 17625543
    [No Abstract]   [Full Text] [Related]  

  • 32. Continuing the evidence-based health care debate in 2006. The progress and price of EBM.
    Miles A; Loughlin M
    J Eval Clin Pract; 2006 Aug; 12(4):385-98. PubMed ID: 16907679
    [No Abstract]   [Full Text] [Related]  

  • 33. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.
    Riechelmann RP; Wang L; O'Carroll A; Krzyzanowska MK
    J Clin Oncol; 2007 Oct; 25(29):4642-7. PubMed ID: 17925561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Authors' self-declared financial conflicts of interest do not impact the results of major cardiovascular trials.
    Aneja A; Esquitin R; Shah K; Iyengar R; Nisenbaum R; Melo M; Matthewkutty S; Sethi SS; Mamdani M; Farkouh ME
    J Am Coll Cardiol; 2013 Mar; 61(11):1137-43. PubMed ID: 23395075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research.
    Jagsi R; Sheets N; Jankovic A; Motomura AR; Amarnath S; Ubel PA
    Cancer; 2009 Jun; 115(12):2783-91. PubMed ID: 19434666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.
    Kesselheim AS; Wang B; Studdert DM; Avorn J
    PLoS Med; 2012; 9(8):e1001280. PubMed ID: 22899894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Publication of clinical trials: accountability and accessibility.
    Tumber MB; Dickersin K
    J Intern Med; 2004 Oct; 256(4):271-83. PubMed ID: 15367169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Insufficient access to research data not acceptable].
    Jørgensen AW; Gøtzsche PC
    Ugeskr Laeger; 2010 May; 172(21):1585. PubMed ID: 20525470
    [No Abstract]   [Full Text] [Related]  

  • 39. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
    Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP
    J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study.
    Tau N; Shochat T; Gafter-Gvili A; Amir E; Shepshelovich D
    Mayo Clin Proc; 2019 Nov; 94(11):2272-2276. PubMed ID: 31685153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.